AKTS 8-K 2026-11-12

Aktis Oncology, Inc. (AKTS) 8-K dated 2026-11-12 — accession 0001193125-26-457045.

Aktis Oncology, Inc. (AKTS) common stock.

Aktis Oncology, Inc. filed a 8-K on 2026-11-12. Accession 0001193125-26-457045.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported AKTS revenue for 2026-06-30 was $3.4M. Net income was -$24.1M. Revenue was up 4.9% from 2026-03-31 to 2026-06-30.

Not investment advice. The AKTS SEC hub lists recent forms. The stock page is the research view.